| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Compugen Ltd (NASDAQ: CGEN)
CGEN Technical Analysis
5
| As on 9th Jun 2023 CGEN STOCK Price closed @ 1.31 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.15 & Strong Sell for SHORT-TERM with Stoploss of 3.59 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CGENSTOCK Price
| Open | 1.33 | Change | Price | % |
| High | 1.36 | 1 Day | 0.04 | 3.15 |
| Low | 1.28 | 1 Week | 0.29 | 28.43 |
| Close | 1.31 | 1 Month | 0.72 | 122.03 |
| Volume | 668268 | 1 Year | -3.12 | -70.43 |
| 52 Week High 4.64 | 52 Week Low 0.57 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CGEN Daily Charts |
CGEN Intraday Charts |
Whats New @ Bazaartrend |
CGEN Free Analysis |
|
|
CGEN Important Levels Intraday
| RESISTANCE | 1.46 |
| RESISTANCE | 1.41 |
| RESISTANCE | 1.38 |
| RESISTANCE | 1.35 |
| SUPPORT | 1.27 |
| SUPPORT | 1.24 |
| SUPPORT | 1.21 |
| SUPPORT | 1.16 |
CGEN Forecast April 2024
| 4th UP Forecast | 4.12 |
| 3rd UP Forecast | 3.22 |
| 2nd UP Forecast | 2.66 |
| 1st UP Forecast | 2.11 |
| 1st DOWN Forecast | 0.51 |
| 2nd DOWN Forecast | -0.04 |
| 3rd DOWN Forecast | -0.6 |
| 4th DOWN Forecast | -1.5 |
CGEN Weekly Forecast
| 4th UP Forecast | 2.47 |
| 3rd UP Forecast | 2.10 |
| 2nd UP Forecast | 1.87 |
| 1st UP Forecast | 1.64 |
| 1st DOWN Forecast | 0.98 |
| 2nd DOWN Forecast | 0.75 |
| 3rd DOWN Forecast | 0.52 |
| 4th DOWN Forecast | 0.15 |
CGEN Forecast2024
| 4th UP Forecast | 9.35 |
| 3rd UP Forecast | 6.77 |
| 2nd UP Forecast | 5.18 |
| 1st UP Forecast | 3.58 |
| 1st DOWN Forecast | -0.96 |
| 2nd DOWN Forecast | -2.56 |
| 3rd DOWN Forecast | -4.15 |
| 4th DOWN Forecast | -6.73 |
Compugen Ltd ( NASDAQ USA Symbol : CGEN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CGEN Business Profile
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Address: Building D, Holon, Israel, 5885849
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service